Alto Neuroscience (NYSE:ANRO) Given Buy Rating at Chardan Capital

Chardan Capital reissued their buy rating on shares of Alto Neuroscience (NYSE:ANRO) in a research report report published on Thursday,Benzinga reports. The firm currently has a $30.00 price target on the stock.

ANRO has been the subject of several other reports. Wall Street Zen lowered Alto Neuroscience from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. Jefferies Financial Group restated a “buy” rating and issued a $35.00 price objective on shares of Alto Neuroscience in a research note on Monday, March 16th. BTIG Research raised their target price on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Finally, Wedbush lifted their target price on Alto Neuroscience from $13.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 17th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.14.

Alto Neuroscience Stock Down 7.9%

Alto Neuroscience stock opened at $21.57 on Thursday. Alto Neuroscience has a fifty-two week low of $1.60 and a fifty-two week high of $25.17. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.69 and a current ratio of 15.69. The firm’s 50-day simple moving average is $19.18 and its 200 day simple moving average is $14.68. The stock has a market cap of $689.03 million, a PE ratio of -9.89 and a beta of 2.01.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Monday, March 16th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.11. Research analysts predict that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

Several institutional investors have recently bought and sold shares of ANRO. Perceptive Advisors LLC grew its holdings in Alto Neuroscience by 1,048.5% during the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after purchasing an additional 1,629,027 shares during the period. 683 Capital Management LLC purchased a new stake in Alto Neuroscience in the fourth quarter worth $1,153,000. Artia Global Partners LP bought a new stake in shares of Alto Neuroscience in the fourth quarter valued at $520,000. Spruce Street Capital LP purchased a new position in shares of Alto Neuroscience during the 4th quarter valued at $3,967,000. Finally, Northwestern Mutual Wealth Management Co. lifted its position in shares of Alto Neuroscience by 14,567.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock valued at $3,786,000 after buying an additional 211,222 shares during the last quarter.

Alto Neuroscience News Roundup

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Multiple firms reaffirmed buy/outperform views and high upside potential: HC Wainwright kept a “buy” and $50 PT, Chardan reaffirmed “buy” with $30 PT, JonesTrading maintained “buy” after lowering its PT to $44, and Robert W. Baird kept an “outperform” while trimming its PT to $38 — these show analyst conviction in Alto’s pipeline despite the miss. Analyst Notes
• Neutral Sentiment: Alto announced it will shift focus toward ALTO-207 and highlighted other pipeline updates following the ALTO-101 topline release — a strategic pivot that could preserve value if follow-on programs show promise, but it’s a longer-term catalyst. ALTO-207 Pivot
• Negative Sentiment: Topline Phase 2 results: ALTO-101 did not achieve statistical significance on the primary endpoint — the direct clinical failure is the main driver of today’s negative price action. Topline Press Release
• Negative Sentiment: Market coverage and headlines amplified the sell-off — multiple outlets reported the failed schizophrenia study and described sizable share declines in pre-market and trading sessions. Expect elevated volume and volatility as investors reassess timelines and probabilities for the rest of the pipeline. Market Reaction
• Negative Sentiment: Some firms became more cautious: Wedbush cut its PT to $21 and set a “neutral” rating — a signal that at least one analyst group sees limited near-term upside after the trial outcome. Wedbush Note

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.